Ponatinib In Heavily Pretreated Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML): Management Of Adverse Events (AEs)
Year: 2013
Type: article
Source: Blood
Authors: Philipp D. Le Coutre, Dong-Wook Kim, Javier Pinilla-Ibarz, Ronald Paquette, Charles Chuah, Franck E. Nicolini, Jane F Apperley, H. Jean Khoury, Moshe Talpaz, John F. Dipersio, Daniel J DeAngelo, Elisabetta Abruzzese, Delphine Rea, Michele Baccarani, Martin C Muller, Carlo Gambacorti-Passerini, Stephanie Lustgarten, Kumiko Yanase, Christopher D Turner, Frank G Haluska, Francois Guilhot, Michael W. Deininger, Andreas Hochhaus, Timothy P. Hughes, John M Goldman, Neil P. Shah, Hagop M. Kantarjian, Jorge E. Cortes
Institutions: Charité - Universitätsmedizin Berlin, The Catholic University of Korea Seoul St. Mary's Hospital, Catholic University of Korea, Moffitt Cancer Center, University of California, Los Angeles, Ronald Reagan UCLA Medical Center, National University of Singapore, Singapore General Hospital, Duke-NUS Medical School, Hôpital Lyon Sud, Imperial College London, Emory University, Winship Cancer Institute, University of Michigan, Washington University in St. Louis, Dana-Farber Cancer Institute, University of Rome Tor Vergata, St. Eugenio Hospital, Hôpital Saint-Louis, IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola, University Medical Centre Mannheim, Medizinische Fakultät Mannheim, Azienda Ospedaliera San Gerardo, University of Milano-Bicocca, ARIAD Pharmaceuticals (United States), Inserm, Centre Hospitalier Universitaire de Poitiers, University of Utah, Huntsman Cancer Institute, Jena University Hospital, South Australia Pathology, South Australian Health and Medical Research Institute, The University of Adelaide, University of California, San Francisco, The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2340174452